Royalty Pharma Bolsters Leadership with Healthcare Investment Banking Veteran
Event summary
- Greg Butz joins Royalty Pharma as EVP, Partnering & Investments in June 2026, bringing two decades of healthcare investment banking experience from Bank of America.
- Chris Hite promoted to Chairman, Partnering & Investments to expand global relationship network and lead transactions.
- Royalty Pharma's portfolio includes royalties on 35+ commercial products and 19 development-stage candidates.
- Recent leadership expansions include Ken Sun as Head of Asia.
The big picture
Royalty Pharma's leadership expansion underscores its strategic focus on scaling its global platform amid increasing transaction activity in the royalty market. With a portfolio spanning 35+ commercial products and 19 development-stage candidates, the company is positioning itself to capitalize on the growing demand for creative funding solutions in the biopharmaceutical industry. The additions of Greg Butz and Ken Sun signal a push towards strengthening both investment banking expertise and geographic reach.
What we're watching
- Execution Risk
- How Greg Butz's integration will impact Royalty Pharma's ability to originate and execute differentiated royalty transactions globally.
- Market Dynamics
- Whether the expanded leadership team can sustain the pace of transaction activity in the rapidly growing royalty market.
- Strategic Alignment
- The extent to which Chris Hite's new role will enhance Royalty Pharma's global relationship network and transaction capabilities.